Table 1.
Immunogen & Adjuvant |
n |
Anti-gp120 (end-point titer) |
Anti-CD4bs (ID50)d |
|
Experiment 1b | No Ag & IFA | 2 | < 20 | < 20 |
CD4bs+ Env & IFA | 4 | > 2500 | 310 (210–470)e | |
CD4bs- Env & IFA | 3 | > 2500 | < 20 | |
Experiment 2c | No Ag & RIBI | 6 | < 100 | < 100 |
CD4bs+ Env & RIBI | 5 | 9060 (2500–12500) | 2160 (630–5900) | |
CD4bs- Env & RIBI | 5 | > 12500 (12500->12500) | < 100 |
aSera were collected two weeks after the final immunizations and tested for reactivity with recombinant gp120LAI in ELISA.
bAll mice were B10.A, except for two BALB/c in the second group. Each animal was immunized 4x i.p. with 5 μg of antigen in IFA.
cAll mice were BALB/c and each was immunized 5x i.p. with 5 μg of antigen in RIBI.
dSerum dilutions that block CD4 binding to gp120LAI by 50%.
eGeometric mean and range of the Ab levels from all mice in each group.